Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of invasive breast cancer that is hormone receptor positive (ER+, PR+/-) and HER2 negative, with no cancer spread to the lymph nodes
- People who are generally well enough to carry out daily activities, based on a standard fitness scale (scores 0–2)
- Women aged 65 years or older
- People whose cancer has been assessed as suitable for breast-conserving surgery (surgery that removes the tumour but keeps most of the breast) and who have chosen to have this type of surgery
- People who are considered suitable for radiation therapy
- People who are considered suitable for hormone-blocking therapy, either tamoxifen or an aromatase inhibitor
- People who are able to swallow tablets and are willing to take hormone-blocking therapy for the 3 months before surgery
- People who are willing to follow certain lifestyle guidelines throughout the study (details available from the trial site)
- People who are willing to sign and date a consent form
- People who are willing to follow all study procedures and are available for the full duration of the study
Who may not be able to join:
- People who have breast cancer in both breasts at the same time
- People whose cancer appears in more than one separate area of the same breast
- People who have previously taken tamoxifen or aromatase inhibitors
- People who have previously had radiation therapy to the same breast being treated
- People who have another cancer that is currently getting worse or requires active chemotherapy or radiation treatment (note: stable, low-risk cancers may be considered on a case-by-case basis — confirm with trial site)
- People who are currently taking or planning to take certain medications that interact with a specific liver enzyme (CYP2D6), such as fluvoxamine or paroxetine, and for whom an alternative hormone-blocking therapy that does not rely on that pathway is not suitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shayna L Showalter, MD, University of Virginia
Phone: 434-243-8101
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants who omit Radiation Therapy (RT) and are non-adherent to Endocrine Therapy (ET); Proportion of participants who are treated with Breast Cancer Surgery (BCS) + RT + AET
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.